The DOL Just Finalized a Rule Forcing Drug Middlemen to Show What They Earn — Does It Reach You?

Drug spending makes up roughly 27% of what employers spend on health benefits, and until now the middlemen who manage those drug benefits have not been required to tell plan sponsors exactly how they get paid. On October 29, 2026, the Department of Labor finalized a rule that changes that for large self-insured plans.

If you run a business with 100 or more workers and a self-insured health plan, this affects you directly. If you buy a fully insured plan, it still shapes the market your insurer operates in. Here is how to tell which group you are in.

What the Labor Department Finalized

The Employee Benefits Security Administration issued the rule under ERISA section 408(b)(2)(B). It requires pharmacy benefit managers (PBMs), and their affiliated brokers and consultants, to disclose their compensation to the fiduciaries of large self-insured employer health plans. The rule follows a proposal made in January, and the department later extended the comment period.

Labor Secretary Keith Sonderling said savings could reach up to $22 billion for employees and employers over the next decade. White House Domestic Policy Council Director Vince Haley described the goal as "No more negotiating in the dark."

Does Your Business Qualify?

Reporting on the rule says a plan is covered if it has at least 100 participants or is sponsored by an employer with at least 100 workers, and if it is self-insured. That means a business with 120 employees that pays claims directly, perhaps with stop-loss coverage, is in scope. A 20-person shop that buys a standard group policy from an insurer is not directly covered.

Self-insured plans are common among mid-sized small businesses because they can lower costs when claims are predictable. Federal figures cited in coverage of the rule say up to 136 million Americans are covered by self-insured plans.

What PBMs Must Now Disclose

• Before signing. PBMs must disclose their services and expected compensation before entering a contract, or at least 90 days before a contract renews or extends.
• Direct and indirect pay. Indirect compensation includes manufacturer rebates, spread pricing, and money clawed back from pharmacies.
• Ongoing reports. Actual compensation must be reported every six months, or quarterly if the plan asks.
• Detail by drug and channel. Spread pricing must be broken out by individual medication and pharmacy channel, along with policies that steer patients toward PBM-owned mail-order or specialty pharmacies, and the reasons lower-cost alternatives are left off formularies.
• Plain language. Disclosures must define jargon and show compensation as a dollar amount or a good-faith estimate, with a machine-readable file available on request.

New Audit Rights

Plan administrators gain the right to audit the accuracy of disclosures once a year, including transaction data and drugmaker contracts, and not only a selective sample. For an owner who has never been able to check a PBM's math, this is the most practical change in the rule.

Liability: Protection With a Duty

The rule includes fiduciary protection. Employers who did not know the PBM failed to disclose, and who reasonably believed the requirements were met, are protected from liability. But once you learn of a problem, you must report it to the Labor Department. Terminating the PBM contract is not required.

In short, you cannot ignore a disclosure gap you have noticed. Keep a record of the reports you receive and the questions you raise.

When It Takes Effect

The rule takes effect 60 days after publication in the Federal Register. Requirements apply to plan years starting July 1, 2027, or later. A calendar-year plan would feel the rule starting with the plan year that begins January 1, 2028, while a plan year beginning July 1, 2027 would be the first covered.

That timing matters because PBM contracts renewing in 2027 will already need the 90-day advance disclosure for later years. Contracts negotiated now can include these terms.

The Industry Pushback

Not everyone supports the rule. The Pharmaceutical Care Management Association argues that the Consolidated Appropriations Act of 2026 already requires drug-by-drug transparency and that the new rule adds duplicative burdens. Expect continued debate, and watch for legal or legislative challenges before the effective date.

What Owners Should Do Now

1. Confirm your plan type. Ask your broker whether the plan is fully insured or self-insured, and how many participants it has.
2. Find your PBM contract. Note the renewal date and the notice period. The 90-day disclosure clock matters for any renewal after the rule applies.
3. Ask your broker about compensation. Brokers and consultants are covered too. Ask how they are paid and whether that is disclosed in writing.
4. Budget for an audit. A once-a-year audit of PBM data takes time or outside help. Decide who on your team, or which advisor, will review it.
5. Keep benefits costs visible in your books. Tracking drug spending as its own line helps you spot savings. Our profit and loss statement guide shows how to structure it.

If You Are Under 100 Workers

You are not directly covered, but transparency rules often change how insurers and PBMs price products for everyone. Ask your insurer how it works with its PBM, and compare quotes at renewal. Our guide on business insurance covers what to ask when you shop coverage.

The Bottom Line

For employers with self-insured plans, the rule shifts power: more information before you sign, regular reports after, and the right to audit. The savings projection of up to $22 billion comes from federal officials and is a forecast, not a guarantee. Use the next several months to learn your plan type, review your PBM contract, and prepare for July 2027. Ask a benefits attorney or ERISA advisor about your specific obligations; this article is not legal advice.

Sources: Becker's Payer Issues, Drug Topics, and reporting on the Department of Labor announcement of October 29, 2026.

Photo by Roberto Sorin on Unsplash